New data shows that the i31-SLNB genomic test can help identify melanoma patients who may safely skip sentinel lymph node biopsy. The test is part of the DecisionDx-Melanoma and combines a 31-gene profile with clinical factors such as age and tumor thickness to predict whether cancer has spread to lymph nodes. In a study of […]
Genomic Test Helps Melanoma Patients Safely Avoid Lymph Node Surgery Read More »
The PANOVA-3 study led to the February 2026 FDA approval of Optune Pax, a new noninvasive device for patients with locally advanced pancreatic cancer. It is used together with standard chemotherapy, including gemcitabine and nab-paclitaxel. The device works by using tumor-treating fields to disrupt cancer cell division. The study showed clear benefits. Median overall survival
New Optune Pax Device Improves Survival in Pancreatic Cancer Read More »
The phase 3 LITESPARK-022 trial shows that combining Belzutifan (Welireg) with Pembrolizumab (Keytruda) after surgery significantly lowers the risk of recurrence in patients with high-risk clear cell renal cell carcinoma. The study found a 28% reduction in the risk of recurrence or death compared to Pembrolizumab alone. Overall survival data are still immature, though early
Belzutifan Plus Keytruda Cuts Recurrence Risk in High-Risk Kidney Cancer Read More »
A new study has identified the RNA helicase DDX5 as an important driver of myeloproliferative neoplasms (MPNs), blood cancers often caused by the JAK2V617F mutation. The research suggests that targeting DDX5 with the small-molecule drug FL118 could help eliminate cancer cells that current treatments fail to destroy. MPNs such as polycythemia vera and myelofibrosis are
New Study Targets DDX5 to Kill Drug-Resistant Cells in Myeloproliferative Neoplasms Read More »
A new study has identified Prolyl 3-hydroxylase 1 (P3H1) as an important driver of pancreatic ductal adenocarcinoma (PDAC) and a potential new treatment target. Researchers found that P3H1 is highly expressed in both human and mouse pancreatic tumors. Patients with higher P3H1 levels tended to have more advanced disease and shorter disease-free survival. In mouse
Study Identifies P3H1 Protein as a New Target in Pancreatic Cancer Treatment Read More »
A Phase II clinical trial suggests that a medically supervised ketogenic diet (MSKD) may help improve outcomes for patients with metastatic pancreatic ductal adenocarcinoma receiving combination chemotherapy with gemcitabine, nab-paclitaxel, and cisplatin. The study included 32 evaluable patients and compared chemotherapy plus the ketogenic diet with chemotherapy plus a usual diet. Results showed encouraging trends
Ketogenic Diet Shows Potential to Improve Survival in Metastatic Pancreatic Cancer Trial Read More »
Researchers are testing PMD-026, a new oral drug that blocks RSK, a protein central to cancer cell growth. High RSK levels are found in about 70% of breast cancers and are linked to poor survival and resistance to standard therapies. RSK promotes tumor growth by speeding up the cell cycle, helping cancer cells repair DNA,
New Drug PMD-026 Shows Promise Against Resistant Breast Cancer Read More »
Physicians have performed the first endoscopic ultrasound-guided microwave ablation (EUS-MWA) for pancreatic cancer in the United States, introducing a new minimally invasive treatment option. Pancreatic cancer is one of the hardest cancers to treat because the pancreas lies deep in the abdomen, and only about 10–15% of patients are eligible for surgery. This new approach
First U.S. Endoscopic Microwave Ablation Performed for Pancreatic Cancer Read More »
A study has found a link between severe respiratory infections and a higher long-term risk of lung cancer. Researchers discovered that serious infections such as COVID-19, influenza, or pneumonia can leave the lungs in a long-lasting inflammatory state that may encourage tumor development. The research showed that patients who were hospitalized for COVID-19 had about
Severe Respiratory Infections Linked to Higher Long-Term Lung Cancer Risk Read More »
Interim results from the Phase 1b MAST trial show that azercabtagene zapreleucel (azer-cel), an off-the-shelf CAR T-cell therapy, is highly active in several B-cell cancers. In heavily pretreated patients who had not received prior CAR T therapy, all 4 chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients achieved partial responses, 3 of 5 marginal zone lymphoma
Off-the-Shelf CAR T Therapy Azer-Cel Shows Strong Activity in B-Cell Cancers Read More »